Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells

Anti-Cancer Drugs

Volumn 20, Issue 8, 2009, Pages 736-745

  Rahim, Rayhana ^a   Strobl, Jeannine S ^b  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b EDWARD VIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

All trans retinoic acid; Breast cancer differentiation; Chloroquine; Histone acetylation; Hydroxychloroquine

Indexed keywords

CHLOROQUINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DIMETHYL SULFOXIDE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE H3; HISTONE H4; HYDROXYCHLOROQUINE; PROTEIN P300; RETINOIC ACID;

ACETYLATION; AMINO TERMINAL SEQUENCE; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG ACETYLATION; DRUG MECHANISM; FEMALE; GROWTH INHIBITION; GROWTH REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MASS SPECTROMETRY; PRIORITY JOURNAL;

ACETYLATION; APOPTOSIS; AUTOPHAGY; BREAST NEOPLASMS; CELL AGING; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; CHLOROQUINE; ENZYME INHIBITORS; FEMALE; HELA CELLS; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; HYDROXYCHLOROQUINE; KI-67 ANTIGEN; MASS SPECTROMETRY; TRETINOIN; TUMOR STEM CELL ASSAY;

EID: 70349319850     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32832f4e50     Document Type: Article

References (51)

1. Klimek VM, Fircanis S, Maslak P, Guernah I, Baum M, Wu N, et al. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res 2008; 14:826-832.
2. Steele NL, Plumb JA, Vidal L, Tjornelund J, Knoblauch P, Rasmussen A, et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 2008; 14:804-810.
3. Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay HJM, et al. Epigenetic drugs as pleiotripic agents in cancer treatment: biomolecular aspects and clinical applications. J Cell Physiol 2007; 212:330-344.
4. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23:3923-3931.
5. Liu T, Kuljaca S, Tee A, Marshall GM. Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rep 2006; 32:157-165.
6. Ito A, Nishino N, Yoshida M. HDAC inhibitors: discovery, development, and clinical impacts. In: Verdin E, editor. Histone deacetylases: transcriptional regulation and other cellular functions. Totowa, New Jersey: Humana Press; 2006. pp. 271-297.
7. Kwon P, Hsu M, Cohen D, Atadja P. HDAC inhibitors: an emerging anticancer therapeutic strategy. In: Verdin E, editor. Histone deacetylases: transcriptional regulation and other cellular functions. Totowa, New Jersey: Humana Press; 2006. pp. 315-332.
8. Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C, Brancolini C. Role of caspases, bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 2003; 278:12579-12589.
9. Boyault C, Sadoul K, Paabion M, Khochbin S. HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene 2007; 26:5468-5476.
10. Zanardi S, Serrano D, Argusti A, Barile M, Puntoni M, Decensi A. Clinical trials with retinoids for breast cancer chemoprevention. Endocrine-Related Cancer 2006; 13:51-68.
11. Munster PN, Srethapakdi M, Moasser MM, Rosen N. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res 2001; 61:2945-2952.
12. Wang Q, Lee D, Sysounthone V, Chandraratna RAS, Christakos S, Korah R, Wieder R. 1,25-Dihydroxyvitamin D3 and retinoic acid analogues induce differentiation in breast cancer cells with function-and cell-specific additive effects. Breast Cancer Res Treat 2001; 67:157-168.
13. Yang X, Phillips DL, Fergusson AT, Nelson WG, Herman JG, Davidson NE. Synergistic activation of functional estrogen receptor (ER)-a by DNA methyltransferase and histone deacetylase inhibitors in human ER-a-negative breast cancer cells. Cancer Res 2001; 61:7025-7029.
14. Liu G, Wu M, Levi G, Ferrari N. Inhibition of cancer cell growth by all-trans retinoic acid and its analog N-(4-hydroxyphenyl)retinamide: a possible mechanism of action via regulation of retinoid receptor expression. Int J Cancer 1998; 78:248-254.
15. Gabrielli BG. Histone deacetylase inhibitors deliver their therapeutic benefit by targeting the cell cycle. Amer Assoc Cancer Res Education Book 2006; 318-321.
16. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000; 92:1210-1216.
17. Lopez C, Alumkal J, Van Hook K. hADA2a and hADA3: new players in beta catenin signaling. Cancer Biol Ther 2008; 7:129-130.
18. Morgan NP, Gudas LJ. Valproic acid, in combination with all-trans retinoic acid and-aza-20-deoxycytidine, restores expression of silenced retinoic acid receptor beta2 in breast cancer cells. Mol Cancer Ther 2005; 4:477-486.
19. Johnson DN, Melkoumian ZK, Lucktong A, Strobl JS. Differentiation of human breast tumor cell lines by quinolines. Joint Meeting of the AACR-NCI-EORTC, Molecular Targets and Cancer Therapeutics 1999; Washington, DC, Abstract #437.
20. Melkoumian ZK, Martirosyan AR, Strobl JS. Myc protein is differentially sensitive to quinidine in tumor versus immortalized breast epithelial cell lines. Int J Cancer 2002; 102:60-69.
21. Zhou Q, Melkoumian ZK, Lucktong A, Moniwa M, Davie JR, Strobl JS. Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1. J Biol Chem 2000; 275:35256-35263.
22. Zhou Q, McCracken MA, Strobl JS. Control of mammary tumor cell growth in vitro by novel cell differentiation and apoptosis agents. Breast Cancer Res Treat 2002; 75:107-117.
23. Martirosyan AR, Rahim-Bata R, Freeman AB, Clarke CD, Howard RL, Strobl JS. Differentiation-inducing quinolines as experimental breast cancer agents in the MCF-7 human breast cancer model. Biochem Pharmacol 2004; 68:1729-1738.
24. Maclean KH, Dorsey FC, Cleveland JL, Kastan MB. Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. J Clin Invest 2008; 118:79-88.
25. Dang CV. Antimalarial therapy prevents Myc-induced lymphoma. J Clin Invest 2008; 118:15-17.
26. Loehberg CR, Thompson T, Kastan MB, Maclean KH, Edwards DG, Kittrell FS, et al. Ataxia telangiectasia-mutated and p53 are potential mediators of chloroquine-induced resistance to mammary carcinogenesis. Cancer Res 2007; 67:12026-12033.
27. Lagneaux L, Delforge A, Dejeneffe M, Massy M, Bernier M, Bron D. Hydroxychloroquine-induced apoptosis of chronic lymphocytic leukemia involves activation of caspase-3 and modulation of Bcl-2/bax ratio. Leuk Lymphoma 2002; 43:1087-1095.
28. Chiang G, Sassaroli M, Louie M, Chen H, Stecher VJ, Sperber VK. Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine. Clin Ther 1996; 18:1080-1092.
29. Savarino A, Gennero L, Sperber K, Boelaert JR. The anti-HIV-1 activity of chloroquine. J Clin Virol 2001; 20:131-135.
30. Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, Chung L, et al. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 2007; 110:313-322.
31. Munster T, Gibbs JP, Shen D, Baethge BA, Botstein GR, Caldwell J, et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum 2002; 46:1460-1469.
32. Augustijns P, Geusens P, Verbeke N. Chloroquine levels in blood during chronic treatment of patients with rheumatoid arthritis. Eur J Clin Pharmacol 1992; 42:429-433.
33. Furst DE, Lindsley H, Baethqe BA, Botstein GR, Caldwell J, Dietz F, Ettlinger R. Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six week trial with 18-week extension. Arthritis Rheum 1999; 42:357-365.
34. Lakshminarayanan S,Walsh S, Mohanraj M, Rothfield N. Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J Rheumatol 2001; 28:102-108.
35. Mok CC, Mak A, Ma KM. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus 2005; 14:106-112.
36. Strobl JS, Melkoumian Z, Peterson VA, Hylton H. The cell death response to gamma-radiation in MCF-7 cells is enhanced by a neuroleptic drug, pimozide. Breast Cancer Res Treat 1998; 51:83-95.
37. Berenbaum MC. What is synergy? Pharmacol Revs 1989; 41:93-141.
38. Martirosyan A, Leonard S, Shi X, Griffith B, Gannett P, Strobl J. Actions of a histone deacetylase inhibitor (NSC3852) (5-nitroso-8-quinolinol) link reactive oxygen species to cell differentiation and apoptosis in MCF-7 human mammary tumor cells. J Pharmacol Expt Ther 2006; 317:546-552.
39. Barnard NJ, Hall PA, Lemoine NR, Kadar N. Proliferation index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical-pathological variables. J Pathol 1987; 152:287-295.
40. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci (U S A) 1995; 92:9363-9367.
41. Fan C, Wang W, Zhao B, Zhang S, Miao J. Chloroquine inhibits growth and induces death in A549 lung cancer cells. Bioorg Med Chem 2006; 14:3218-3222.
42. Hu C, Solomon VR, Ulibarri G, Lee H. The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine. Bioorg Med Chem 2008; 16:7888-7893.
43. Briceno E, Calderon A, Sotelo J. Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme. Surg Neurol 2007; 67:388-391.
44. Zhang K, Williams KE, Huang L, Yau P, Siino JS, Bradbury EM, et al. Histoneacetylation and deacetylation: identification of acetylation and methylation sites of HeLa histone H4 by mass spectrometry. Mol Cell Proteomics 2002; 1:500-508.
45. Ornaghi P, Rotili D, Sbardella G, Mai A, Filetici P. A novel Gcn5p inhibitor represses cell growth, gene transcription and histone acetylation in budding yeast. Biochem Pharmacol 2005; 70:911-917.
46. Mai A, Rotil D, Tarantino D, Ornaghi P, Tosi F, Vicidomini C, et al. Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties. J Med Chem 2006; 49:6897-6907. (Pubitemid 44749755)
47. Eliseeva ED, Valkov V, Jung M, Jung MO. Characterization of novel inhibitors of histone acetyltransferase. Mol Cancer Ther 2007; 6:2391-2398.
48. Smith AT, Livingston MR, Mai A, Filetici P, Queener SF, Sullivan WJ Jr. Quinoline derivative MC1626, a putative GCN5 histone acetyltransferase (HAT) inhibitor, exhibits HAT-independent activity against. Toxoplasma gondii Antimicrob Agents Chemother 2007; 51:1109-1111.
49. Stimson L, Rowlands MG, Newbatt YM, Smith NF, Raynoud FI, Rogers P, et al. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. Mol Cancer Ther 2005; 4:1521-1532.
50. Arce JD, Gockel-Krzikalla E, Rosl F. Retinoic acid receptor-beta silences human papilloma virus-18 oncogene expression by induction of de novo methylation and heterochromatization of the viral control region. J Biol Chem 2007; 282:28520-28529.
51. Balasubramanyam K, Swaminathan V, Ranganathan A, Kundu TK. Small molecule inhibitors of histone acetyltransferase p300. J Biol Chem 2003; 278:19134-19140.